What You Ought to Know:
– Flatiron Health, a healthtech firm centered on reworking scientific analysis by way of know-how that integrates analysis into on a regular basis care, has introduced a strategic partnership with Massive Bio, a worldwide chief in utilizing synthetic intelligence to streamline affected person identification and recruitment for scientific trials.
– The partnership goals to develop affected person identification capabilities and enhance scientific trial enrollment throughout the U.S.
Improve Affected person Identification Capabilities and Companies
This collaboration will make the most of Large Bio’s U.S.-based database to determine sufferers who could also be eligible for scientific trials however aren’t at present enrolled and are situated close to collaborating trial websites. These sufferers will then be referred to Flatiron’s analysis websites, the place they are often onboarded as new sufferers and evaluated for potential trial enrollment utilizing Flatiron’s know-how and centralized affected person identification companies.
“At Large Bio, our mission is to make entry to scientific trials actually patient-centric, guaranteeing the proper affected person is matched to the proper trial on the proper time—irrespective of the place they reside,” stated Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Large Bio. “By pairing our AI-driven platform and concierge companies with Flatiron Well being’s in depth analysis infrastructure, we will help physicians and care groups expedite trial enrollment, cut back disparities in entry, and enhance outcomes for extra sufferers.”
